Upstream Bio Releases Topline Data From Phase 2 VALIANT Trial Of Verekitug For Severe Asthma, Meeting The Primary Endpoint Of Annualized Asthma Exacerbation Rate

-1.67%

UpStream Bio

UPB

7.67

-1.67%

Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing.
Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with both dose regimens.
Verekitug was generally well tolerated, with a safety profile consistent with prior studies.
Over 90% of eligible patients have rolled over to the Phase 2 VALOUR long-term extension study.
Upstream Bio to advance verekitug into Phase 3 trials in severe asthma and CRSwNP following planned regulatory interactions

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.